Detonating T-ALL

In this issue of Blood, Tran Quang et al show treatment with anti-CD3 anti-bodies produces potent antileukemic effects in mouse xenograft models of disseminated T-cell acute lymphoblastic leukemia (T-ALL).1 Using several high -tumor-burden patient-derived xenograft (PDX) models of T-ALL, the authors demonstrate that 5 daily injections of anti-CD3 antibodies induced temporary regression of leukemia and prolonged mouse survival. Combining the anti-body injections with vincristine and dexamethasone further enhanced these effects, resulting in complete eradication of established T-ALL in most animals. These results suggest anti-CD3 antibodies can be explored as a treatment of patients with sCD31 T-ALL.